Bristol-Myers Hits Sandoz Over Generic Hepatitis Drug

Law360, New York (June 21, 2012, 7:39 PM EDT) -- Bristol-Myers Squibb Co. on Thursday filed suit in Delaware federal court alleging Sandoz Inc.'s plan to make a generic version of the hepatitis B drug Baraclude would lead to infringement of BMS' patent for the medication.

BMS said in its complaint that unless Sandoz is blocked from carrying through with plans to make entecavir — the active ingredient in Baraclude — which it submitted in an abbreviated new drug application to the U.S. Food and Drug Administration, the generic maker would infringe BMS’s U.S. Patent Number...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.